A central question in innate immunity is how do the various innate immune systems distinguish between potential targets and the host. The molecular mechanisms by which the molecules of these systems recognize and elicit responses (i.e., to potential pathogens) or prevent responses (i.e., to the host) has recently been recognized to be fundamental to understanding target selection by the adaptive immune systems of higher organisms. Complement is the major non-cellular system of innate immunity in humans. Complement has the ability to kill directly, to mark the target with ligands (C3b, iC3b, C3d) for receptors of the cellular innate immune system (CD35, CD21, CD11b, CD11c) and to stimulate numerous cellular and humoral responses from systems of acquired immunity. The alternative pathway of complement is the major innate defense system of complement in adults. It uses a complex set of control proteins to select its targets and to regulate amplification of bound C3 fragments. The cell-bound regulators (DAF, CR1, CD59, MCP) and humoral control factors (factors H and I) protect host cells from cytolysis by inadvertent or misdirected complement activation. Biological particles lacking these regulators may or may not be activators of the alternative pathway of complement. The six proteins of the human alternative pathway of complement are capable of discriminating between host and targets and initiating activation without the aid of immunoglobulins, lectins, receptors or other products of adaptive immunity. The mechanism of alternative pathway host/target discrimination has been the subject of intense study since the discovery in the 1970's of a complement activating pathway that did not rely on antibodies for target identification. It is now known that one of the six proteins, factor H, plays the major discriminatory role in this pathway. The goal of the proposed research is to understand the molecular mechanisms of the host and target discrimination by the alternative pathway of human complement, to understand the control mechanisms which limit or enhance activation and to describe the alternative pathway activation and control processes leading to C5 activation. The two major aims of this proposal are: l) to describe in molecular detail the functions of the recently discovered multiple sites on factor H and to understand how these sites interact with C3b and host and target markers to control activation of the alternative pathway, and 2) to study the structure and function of the alternative pathway C5 convertase enzymes including their formation, subunit structures, enzymatic properties and the normal processes that control convertase formation and inactivation.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK035081-19
Application #
6717616
Study Section
Allergy and Immunology Study Section (ALY)
Program Officer
Badman, David G
Project Start
1984-09-01
Project End
2006-12-31
Budget Start
2004-01-01
Budget End
2004-12-31
Support Year
19
Fiscal Year
2004
Total Cost
$250,077
Indirect Cost
Name
University of Texas Health Center at Tyler
Department
Biochemistry
Type
Other Domestic Higher Education
DUNS #
800772337
City
Tyler
State
TX
Country
United States
Zip Code
75708
Ferreira, Viviana P; Fazito Vale, Vladimir; Pangburn, Michael K et al. (2016) SALO, a novel classical pathway complement inhibitor from saliva of the sand fly Lutzomyia longipalpis. Sci Rep 6:19300
Singh, Sanjay K; Thirumalai, Avinash; Hammond Jr, David J et al. (2012) Exposing a hidden functional site of C-reactive protein by site-directed mutagenesis. J Biol Chem 287:3550-8
Hadders, Michael A; Bubeck, Doryen; Roversi, Pietro et al. (2012) Assembly and regulation of the membrane attack complex based on structures of C5b6 and sC5b9. Cell Rep 1:200-7
Takeda, Katsuyuki; Thurman, Joshua M; Tomlinson, Stephen et al. (2012) The critical role of complement alternative pathway regulator factor H in allergen-induced airway hyperresponsiveness and inflammation. J Immunol 188:661-7
Renner, Brandon; Ferreira, Viviana P; Cortes, Claudio et al. (2011) Binding of factor H to tubular epithelial cells limits interstitial complement activation in ischemic injury. Kidney Int 80:165-73
Cortes, Claudio; Ferreira, V P; Pangburn, Michael K (2011) Native properdin binds to Chlamydia pneumoniae and promotes complement activation. Infect Immun 79:724-31
Thurman, Joshua M; Renner, Brandon; Kunchithapautham, Kannan et al. (2010) Aseptic injury to epithelial cells alters cell surface complement regulation in a tissue specific fashion. Adv Exp Med Biol 664:151-8
Ferreira, Viviana P; Pangburn, Michael K; Cortes, Claudio (2010) Complement control protein factor H: the good, the bad, and the inadequate. Mol Immunol 47:2187-97
Renner, Brandon; Coleman, Kathrin; Goldberg, Ryan et al. (2010) The complement inhibitors Crry and factor H are critical for preventing autologous complement activation on renal tubular epithelial cells. J Immunol 185:3086-94
Rohrer, Bärbel; Long, Qin; Coughlin, Beth et al. (2010) A targeted inhibitor of the complement alternative pathway reduces RPE injury and angiogenesis in models of age-related macular degeneration. Adv Exp Med Biol 703:137-49

Showing the most recent 10 out of 58 publications